Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.70 |
| ▸ | HPGD | P15428 | 1/20 | 0.70 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.70 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.61 |
| ▸ | EGFR | P00533 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | GFER | P55789 | 1/20 | 0.55 |
| ▸ | ALPL | P05186 | 1/20 | 0.53 |
| ▸ | ALPI | P09923 | 1/20 | 0.53 |
| ▸ | ALPG | P10696 | 1/20 | 0.53 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.53 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | MPL | P40238 | 2/20 | 0.43 |
| ▸ | NSD2 | O96028 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dobesilic Acid SCHEMBL78222 | 1.00 | LMNA (0.70) | LMNAHSD17B10HPGDHIF1APTGS1 | |
| Dobesilic Acid SCHEMBL232087 | 0.98 | LMNA (0.72) | LMNAHSD17B10HPGDHIF1APTGS1 | |
| Dobesilic Acid SCHEMBL29389625 | 0.98 | LMNA (0.72) | LMNAHSD17B10HPGDHIF1APTGS1 | |
| Dobesilic Acid SCHEMBL9790423 | 0.95 | LMNA (0.70) | LMNAHSD17B10HPGDHIF1APTGS1 | |
| Dobesilic Acid SCHEMBL10589964 | 0.95 | HSD17B10 (0.70) | LMNAHSD17B10HPGDHIF1APTGS1 | |
| Dobesilic Acid SCHEMBL344443 | 0.95 | LMNA (0.70) | LMNAHSD17B10HPGDHIF1APTGS1 | |
| Dobesilic Acid SCHEMBL214799 | 0.95 | LMNA (0.70) | LMNAHSD17B10HPGDHIF1APTGS1 | |
| Dobesilic Acid SCHEMBL78224 | 0.95 | LMNA (0.70) | LMNAHSD17B10HPGDHIF1APTGS1 | |
| Dobesilic Acid SCHEMBL15364076 | 0.95 | LMNA (0.70) | LMNAHSD17B10HPGDHIF1APTGS1 | |
| Dobesilic Acid SCHEMBL866670 | 0.95 | LMNA (0.70) | LMNAHSD17B10HPGDHIF1APTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110257264-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR TREATING ACTINIC KERATOSIS | ACTION MEDICINES (ES) | 2011-10-20 | — | — | US | claimed |
| US-20110196040-A1 | Skin Penetration Enhancing Systems for Polar Drugs | ACTION MEDICINES S.L. (ES) | 2011-08-11 | — | — | US | claimed |
| US-20120077785-A1 | METHODS OF USE FOR 2,5-DIHYDROXYBENZENE SULFONIC ACID COMPOUNDS FOR THE TREATMENT OF CANCER, ROSACEA AND PSORIASIS | ACTION MEDICINES (ES) | 2012-03-29 | — | — | US | disclosed |
| US-20120015912-A1 | USE OF 2,5-DIHYDROXYBENZENE FOR THE TREATMENT OF OCULAR DISEASES | ACTION MEDICINES (ES) | 2012-01-19 | — | — | US | disclosed |
| US-20110257264-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR TREATING ACTINIC KERATOSIS | ACTION MEDICINES (ES) | 2011-10-20 | — | — | US | disclosed |
| US-20110196040-A1 | Skin Penetration Enhancing Systems for Polar Drugs | ACTION MEDICINES S.L. (ES) | 2011-08-11 | — | — | US | disclosed |
| US-20110152222-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF ARTHRITIS AND PAIN | SANCHEZ PEDRO CUEVAS | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077785-A1 | METHODS OF USE FOR 2,5-DIHYDROXYBENZENE SULFONIC ACID COMPOUNDS FOR THE TREATMENT OF CANCER, ROSACEA AND PSORIASIS | IL2, IL2RA, IL5 | LMNA 4181/4885HSD17B10 1497/4885HPGD 2149/4885 |
| US-20110196040-A1 | Skin Penetration Enhancing Systems for Polar Drugs | ABCB11, KCNK5, KCNQ5 | LMNA 3019/4885HSD17B10 2486/4885HPGD 2531/4885 |
| US-20120015912-A1 | USE OF 2,5-DIHYDROXYBENZENE FOR THE TREATMENT OF OCULAR DISEASES | ALDH1A2, CRYAB, HSD17B14 | LMNA 2802/4885HSD17B10 104/4885HPGD 134/4885 |
| US-20110257264-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR TREATING ACTINIC KERATOSIS | CYP8B1, DERA, KRT18 | LMNA 1346/4885HSD17B10 125/4885HPGD 212/4885 |
| US-20110152222-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF ARTHRITIS AND PAIN | CYP8B1, CYP26B1, UGT2B7 | LMNA 3452/4885HSD17B10 117/4885HPGD 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.